GLP-2: The Other Incretin Hormone and Why It Matters for Gut Health

GLP-2: The Other Incretin Hormone and Why It Matters for Gut Health

By Dr. Onikepe Adegbola, MD PhD

Everyone knows about GLP-1. Ozempic, Wegovy, Mounjaro — the GLP-1 receptor agonists have become some of the most prescribed medications on the planet. But there's a sibling hormone that gets almost no attention outside of gastroenterology circles: GLP-2.

GLP-2 comes from the same gene as GLP-1. It's produced by the same intestinal L-cells. It's released in response to the same meals. But where GLP-1 became famous for blood sugar control and weight loss, GLP-2 took a completely different path — one focused on gut repair, intestinal growth, and nutrient absorption.

Understanding GLP-2 matters, especially if you're on GLP-1 therapy and experiencing GI side effects. Here's what this hormone does and why gastroenterologists have been paying attention to it for decades.

What Is GLP-2? The Biology

GLP-2 stands for glucagon-like peptide-2. Like GLP-1, it's derived from the proglucagon gene (GCG) — a single gene that produces several different hormones depending on which tissue processes it.

In the intestinal L-cells, the proglucagon gene produces both GLP-1 and GLP-2 simultaneously. When you eat a meal, those L-cells release both hormones into circulation at the same time. Same stimulus. Same cells. Completely different downstream effects.

GLP-1 travels to the brain and pancreas, where it suppresses appetite, stimulates insulin secretion, and slows gastric emptying. You know this story already.

GLP-2 stays more local. Its primary targets are in the intestine itself:

• Intestinal epithelial proliferation. GLP-2 stimulates the growth of the intestinal lining — the villous epithelium — increasing the surface area available for nutrient absorption. In animal studies, GLP-2 administration causes measurable increases in intestinal length and mucosal thickness within days.
• Reduced intestinal permeability. GLP-2 tightens the junctions between intestinal cells, reducing what's colloquially called "leaky gut." In clinical terms, it enhances barrier function.
• Enhanced blood flow. GLP-2 increases mesenteric blood flow — the blood supply to the intestines — which supports nutrient transport and tissue repair.
• Reduced apoptosis. GLP-2 promotes cell survival in the intestinal lining, slowing the normal rate of cell death that turns over the gut epithelium every 3-5 days.
• Slowed gastric emptying. Like GLP-1, GLP-2 slows how quickly food leaves the stomach, though through different signaling pathways.

Think of GLP-2 as the intestine's growth and repair signal. It says: "There's food coming in. Build more absorptive surface. Strengthen the barrier. Increase blood flow. Get ready."

GLP-2 vs. GLP-1: Same Gene, Different Missions

The relationship between these two hormones is fascinating to me as a physician-scientist. They come from the same precursor, they're released together, but they serve almost opposite roles in the bigger picture.

Here's how they compare:

• GLP-1 tells the body: slow down food intake, release insulin, suppress glucagon, lose weight. It's a metabolic brake.
• GLP-2 tells the intestine: grow, repair, absorb more. It's a gut-building accelerator.

In a healthy system, these signals balance each other. You eat. GLP-1 helps your body process the calories metabolically. GLP-2 helps your intestine absorb the nutrients from that food efficiently.

The clinical relevance: when we give patients GLP-1 receptor agonists like semaglutide or tirzepatide, we're supercharging one side of this equation (the metabolic/appetite suppression side) without directly affecting the GLP-2 side. The intestine still needs to absorb nutrients from whatever food the patient does eat — and with reduced food intake, efficient absorption matters more.

Teduglutide: The GLP-2 Drug

While GLP-1 agonists like semaglutide grabbed the spotlight, GLP-2 got its own pharmaceutical moment. Teduglutide (brand name Gattex in the US, Revestive in Europe) is a GLP-2 analog — a modified version of GLP-2 that resists breakdown by the enzyme DPP-4 and lasts longer in the body.

Teduglutide is FDA-approved for short bowel syndrome (SBS). Patients with SBS have had significant portions of their intestine surgically removed — often due to Crohn's disease, mesenteric ischemia, or trauma. With too little intestine to absorb adequate nutrition, they depend on intravenous parenteral nutrition (TPN) to survive.

Teduglutide changed outcomes for these patients:

• Clinical trials showed that daily teduglutide injections reduced parenteral nutrition requirements by 20-100% in many patients.
• Some patients achieved full enteral autonomy — meaning they could absorb enough nutrition through their remaining intestine to stop IV nutrition entirely.
• The mechanism: teduglutide stimulates growth of the remaining intestinal lining, increasing absorptive capacity in whatever gut tissue the patient has left.

The implications extend beyond SBS. Researchers are investigating GLP-2 analogs for inflammatory bowel disease (where gut barrier repair is a therapeutic target), chemotherapy-induced mucositis, and neonatal intestinal conditions.

Why GLP-2 Matters If You're on GLP-1 Medication

Here's where this gets practical. If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound, you're experiencing the effects of pharmacological GLP-1 activation: reduced appetite, slower gastric emptying, and yes — GI side effects.

The GI side effects of GLP-1 medications (nausea, diarrhea, constipation, bloating) are not directly caused by GLP-2 deficiency. But the underlying biology is related. When you eat less, the natural stimulus for GLP-2 secretion is reduced. Less food hitting the L-cells means less GLP-2 production. Less GLP-2 means less intestinal growth and repair signaling.

Whether this reduced GLP-2 stimulus has clinically meaningful consequences for GLP-1 medication users is an active area of investigation. But the concept is straightforward: your gut lining turns over every few days and needs nutritional support and signaling to maintain itself.

What we do know: patients on GLP-1 medications who support their gut health proactively — through adequate nutrition, fiber intake, and targeted supplementation — tend to tolerate treatment better and report fewer GI complaints.

Casa de Sante GLP-1 supplements were formulated with exactly this context in mind. Supporting digestive function, nutrient absorption, and gut barrier health while on GLP-1 therapy addresses the practical gap that reduced food intake creates.

The Future of GLP-2 Research

GLP-2 research is moving in several directions that bear watching:

• IBD applications. GLP-2's ability to repair intestinal barrier function makes it a natural candidate for inflammatory bowel disease. Early studies suggest potential for mucosal healing in Crohn's disease, though large-scale trials are still needed.
• Combination therapies. Some researchers are exploring whether co-administering GLP-1 and GLP-2 analogs could provide metabolic benefits while simultaneously supporting gut health. This is still preclinical, but the logic is compelling.
• Gut microbiome interactions. GLP-2 signaling appears to interact with the gut microbiome, influencing bacterial composition and vice versa. Understanding these interactions could lead to new approaches for managing GI conditions.
• Post-bariatric surgery. After gastric bypass or sleeve gastrectomy, the gut undergoes significant adaptation. GLP-2's role in intestinal adaptation post-surgery is being studied as a potential adjunct therapy.

For a hormone that's lived in the shadow of its famous sibling, GLP-2 is quietly building a meaningful clinical story. It may never achieve the blockbuster status of GLP-1 agonists, but for patients with intestinal conditions — and potentially for the broader GLP-1 medication user population — it fills a distinct and important role.

Frequently Asked Questions

Is GLP-2 the same as GLP-1?

No. GLP-1 and GLP-2 are different hormones produced from the same proglucagon gene. They're co-secreted from intestinal L-cells but have distinct receptors and functions. GLP-1 primarily affects blood sugar regulation, appetite, and metabolism. GLP-2 primarily targets the intestinal lining, promoting growth, repair, and nutrient absorption.

Can I take a GLP-2 supplement?

There is no over-the-counter GLP-2 supplement. Teduglutide (the GLP-2 analog) is a prescription injectable medication approved specifically for short bowel syndrome. It's administered by daily subcutaneous injection and requires medical supervision. Supporting natural GLP-2 production through adequate nutrition and a healthy gut is the best non-pharmacological approach.

Does food affect GLP-2 levels?

Yes. GLP-2 is released in response to food intake, particularly nutrients reaching the lower small intestine and colon. Fiber, short-chain fatty acids from gut bacteria, and mixed meals all stimulate GLP-2 secretion. Eating less (as happens on GLP-1 medication) reduces this stimulation, which is one reason gut-supportive nutrition matters during GLP-1 therapy.

What are the side effects of GLP-2 therapy (teduglutide)?

In clinical trials, the most common side effects of teduglutide included abdominal pain, injection site reactions, nausea, headache, and intestinal obstruction (in patients predisposed to this due to their underlying condition). Because GLP-2 promotes intestinal cell growth, patients require monitoring for intestinal polyps. This is a medically supervised therapy, not suitable for general use.

Will GLP-2 medications be used for weight management?

Currently, no. GLP-2's effects are focused on gut growth and repair, not weight loss. In fact, by enhancing nutrient absorption, GLP-2 could theoretically promote weight maintenance rather than loss. However, research into dual GLP-1/GLP-2 approaches is still early. The immediate clinical trajectory for GLP-2 is in intestinal conditions, not metabolic disease.